Relationship Between Eating Patterns, Body Composition and the Detection of Fatty Liver in Children and Adolescents With Trisomy 21: LiverTy Project (LiverTy)

April 29, 2025 updated by: Lorena Lopez Lora, IMDEA Food

Childhood Obesity is a Global Health Issue, Especially in Children With Trisomy 21 (T21), Who Face Higher Risks of Non-alcoholic Fatty Liver Disease (NAFLD). Early Detection Using Non-invasive Tools Like Liver Elastography is Key. Evaluating Dietary Patterns With the 24-hour Food Recall and KIDMED Helps Guide Personalized Interventions

Childhood obesity is a growing public health issue affecting millions of children worldwide, increasing the risk of metabolic and cardiovascular diseases in adulthood. This problem is particularly concerning in children and adolescents with Down syndrome (trisomy 21, T21), who have a higher predisposition to fat accumulation due to genetic, metabolic, and behavioral factors. However, assessing their nutritional status and body composition is challenging, as conventional tools such as body mass index (BMI) may not accurately reflect adiposity in this population.

One of the most severe risks associated with obesity in children with T21 is non-alcoholic fatty liver disease (NAFLD). This condition is characterized by fat accumulation in the liver without significant alcohol consumption and is closely linked to insulin resistance, dyslipidemia, and pro-inflammatory states. If not detected early, NAFLD can progress to more severe liver diseases such as fibrosis or cirrhosis. In individuals with T21, the prevalence of NAFLD may be underestimated due to the difficulty in properly assessing body composition and metabolism.

Since NAFLD diagnosis traditionally requires invasive procedures such as liver biopsy, this study proposes using non-invasive techniques, such as liver elastography, to assess liver health in children and adolescents with T21. Additionally, dietary habits will be analyzed using standardized tools to establish the relationship between nutrition, body composition, and NAFLD risk in this population.

Study Hypothesis:

The main hypothesis is that obesity and inadequate dietary patterns increase the risk of NAFLD in our participants with T21. The investigators also believe that liver elastography will enable the early detection of fat accumulation in the liver and other signs of liver disease, facilitating timely intervention.

Study Objectives:

The primary objective of this study is to evaluate the presence and severity of NAFLD in children and adolescents with T21 using non-invasive diagnostic techniques and nutritional assessment methods.

Specifically, the study will analyze:

  • Liver health: Measurement of liver fat and stiffness using elastography. Body composition: Anthropometric evaluation and adiposity analysis. Dietary habits: 24-hour food recall and KIDMED questionnaire to assess adherence to the Mediterranean diet.
  • Relationship between obesity and NAFLD: Identification of metabolic and behavioral risk factors.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

  1. Study Design

    This is an observational cross-sectional study in which participants with T21, with and without obesity, will be evaluated without direct therapeutic intervention.

  2. Registration and Evaluation Procedures

    2.1 Clinical Assessments

    • Liver Elastography: Assessment of liver stiffness using FibroScan. Hepatic elastography is a non-invasive imaging technique used to assess liver stiffness and fat content, which correlates with liver fibrosis. It is particularly useful in pediatric populations for evaluating liver diseases such as non-alcoholic fatty liver disease (NAFLD), viral hepatitis, and other chronic liver conditions. FibroScan measures ultrasound signal attenuation due to liver fat content. Higher values (db/m) indicate more fat deposition.
    • Anthropometric Measurements: Weight, height, body mass index (BMI), abdominal circumference.
    • Body composition parameters measured by bioimpedance:

    Adipose tissue %, muscle mass (kg) and visceral fat index.

    2.2. Nutritional Evaluation:

    • 24-hour dietary recall. To estimate nutrient consumption, dietary intake from the 24-hour dietary recall will be converted given the use of nutritional composition tables and validated food composition software (DIAL).
    • KIDMED questionnaire for adherence to the Mediterranean diet.

    The KIDMED (Mediterranean Diet Quality Index) questionnaire is a widely used tool to assess adherence to the Mediterranean diet among children and adolescents. It consists of 16 items that evaluate various dietary habits. Each item is scored as follows:

    Positive connotation items (reflecting healthy Mediterranean dietary habits): Each receives a score of +1.

    Negative connotation items (indicating departure from Mediterranean dietary principles): Each receives a score of -1.

    The total KIDMED score ranges from -4 to 12. Based on the total score, adherence to the Mediterranean diet is categorized into three levels:

    High adherence: Scores of ≥8. Medium adherence: Scores between 4 and 7. Low adherence: Scores of ≤3.

  3. Quality Assurance Plan

    Electronic data management system with automatic validations to prevent data entry errors.

  4. Sample Size Evaluation

    It is estimated that a sample of 17 participants with T21 and 17 participants in the control group reaches 80% statistical power in detecting significant differences in the detection of fatty liver.

  5. Statistical Analysis Plan

    • Descriptive statistics will be used to characterize the sample.
    • Correlation tests and logistic regression will be performed to assess the relationship between NAFLD and metabolic factors.
    • Analysis of variance (ANOVA) will be used to compare parameters among subgroups.

  6. Ethical and Safety Considerations

    • Approval from the Research Ethics Committee.
    • Data management in compliance with the General Data Protection Regulation (GDPR).

This protocol will allow us to evaluate the relationship between obesity, dietary patterns, and NAFLD in children with T21, providing key information for future preventive strategies.

Study Type

Observational

Enrollment (Estimated)

34

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Madrid, Spain
        • Fundación Jerome Lejeune

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Participants will be selected who are patients at the Jerome Lejeune Foundation center or students in special education centers who wish to participate. For the control group, dissemination will be carried out among workers with children of the required age range.

Description

Inclusion Criteria:

  • Children (5-10 years), and adolescents (11-19) andyoung adults (20-22 years) of bothSexes
  • 5 to 22 years old
  • Diagnosis of trisomy 21 or other intellectual disability of genetic origin for the group of the cases.
  • BMI: 17-40 Kg/m2
  • Signing of the informed consent by the parents or guardians.

Exclusion Criteria:

  • Not meeting the inclusion criteria
  • Have previous liver pathology.
  • Be under any medical treatment that
  • Modify composition parameters Body: GLP-1 analogues and derivatives.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Case group.
Children and adolescents (ages 5-22) with Down syndrome (T21) who may have or not have NAFLD.
Other: To evaluate fat liver content in the cases/controls population.
The studied population includes participants aged 5-22 years old with/without T21 Down Syndrome.
Control group.
Children and adolescents (ages 5-22) without Down syndrome (T21) who may have or not have NAFLD.
Other: To evaluate fat liver content in the cases/controls population.
The studied population includes participants aged 5-22 years old with/without T21 Down Syndrome.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Liver fat content.
Time Frame: 3 months.
To estimate liver fat content with hepatic elastography (FibroScan), CAP measurement will be used. Control population CAP value would range between 160-184 db/m and cases ≥ 184 db/m.
3 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body weight.
Time Frame: 3 months.
Body weight (kg) will be assessed with a calibrated scale with the purpose of obtaining descriptive data of both populations, cases and controls.
3 months.
Height.
Time Frame: 3 months.
Height (cm) will be assessed with a calibrated stadiometer with the purpose of obtaining descriptive data of both populations, cases and controls.
3 months.
Body Mass Index.
Time Frame: 3 months.
Body Mass Index (kg/m*2) will be calculated with the body weight and height.
3 months.
Waist circumference.
Time Frame: 3 months.
Waist circumference (cm) will be assessed with a measuring tape with the purpose of obtaining descriptive data of both populations, cases and controls.
3 months.
Adipose tissue (%).
Time Frame: 3 months.
Adipose tissue (%) will be estimated with bioimpedance with a calibrated TANITA with the purpose of obtaining descriptive data of both populations, cases and controls.
3 months.
Visceral fat index.
Time Frame: 3 months.
Visceral fat index will be estimated with bioimpedance with a calibrated TANITA with the purpose of obtaining descriptive data of both populations, cases and controls.
3 months.
Muscle mass.
Time Frame: 3 months.
Muscle mass (kg) will be estimated with bioimpedance with a calibrated TANITA with the purpose of obtaining descriptive data of both populations, cases and controls.
3 months.
24-hour dietary quality evaluation.
Time Frame: 3 months.
24-hour dietary quality will be assessed with a validated 24-h recall food questionnaire in both populations, cases and controls.
3 months.
Mediterranean diet adherence.
Time Frame: 3 months.
Mediterranean diet adherence will be assessed with a validated mediterranean food questionnaire for pediatric population (KIDMED) in both, cases and controls.
3 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

IMDEA Food

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2025

Primary Completion (Estimated)

June 30, 2025

Study Completion (Estimated)

July 30, 2025

Study Registration Dates

First Submitted

February 28, 2025

First Submitted That Met QC Criteria

March 14, 2025

First Posted (Actual)

March 21, 2025

Study Record Updates

Last Update Posted (Actual)

May 2, 2025

Last Update Submitted That Met QC Criteria

April 29, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IMD: PI-070

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Relevant data obtained on the relationship of fatty liver in the studied population

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe